Jang Han Rhee - Net Worth and Insider Trading

Jang Han Rhee Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jang Han Rhee owns 2 companies in total, including Rexahn Pharmaceuticals Inc (REXN) , and Ocuphire Pharma Inc (OCUP) .

Click here to see the complete history of Jang Han Rhee’s form 4 insider trades.

Insider Ownership Summary of Jang Han Rhee

Ticker Comapny Transaction Date Type of Owner
REXN Rexahn Pharmaceuticals Inc 2005-05-13 director
OCUP Ocuphire Pharma Inc 2005-05-13 director

Jang Han Rhee Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jang Han Rhee Ownership Network

Ownership Network List of Jang Han Rhee

No Data

Ownership Network Relation of Jang Han Rhee

Insider Network Chart

Jang Han Rhee Owned Company Details

What does Rexahn Pharmaceuticals Inc do?

Who are the key executives at Rexahn Pharmaceuticals Inc?

Jang Han Rhee is the director of Rexahn Pharmaceuticals Inc. Other key executives at Rexahn Pharmaceuticals Inc include Chief Medical Officer Ely Benaim , Chief Business Officer Lisa Nolan , and director & President and CEO Douglas J Swirsky .

Rexahn Pharmaceuticals Inc (REXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rexahn Pharmaceuticals Inc (REXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rexahn Pharmaceuticals Inc (REXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rexahn Pharmaceuticals Inc (REXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Rexahn Pharmaceuticals Inc Insider Transactions

No Available Data

Jang Han Rhee Mailing Address

Above is the net worth, insider trading, and ownership report for Jang Han Rhee. You might contact Jang Han Rhee via mailing address: 9620 Medical Center Drive, Rockville Md 20850.

Discussions on Jang Han Rhee

No discussions yet.